(3R)-3-ethyl-6-fluoro-4-(4-methoxybenzoyl)-3,4-dihydroquinoxalin-2(1H)-one | 874216-47-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (3R)-3-ethyl-6-fluoro-4-(4-methoxybenzoyl)-3,4-dihydroquinoxalin-2(1H)-one
• 英文别名: (3R)-3-ethyl-6-fluoro-4-(4-methoxybenzoyl)-1,3-dihydroquinoxalin-2-one
• CAS: 874216-47-4
• 化学式: C₁₈H₁₇FN₂O₃
• 分子量: 328.343
• InChiKey: CDIFJZXVRJRPSZ-OAHLLOKOSA-N

物化性质

• 沸点：
  537.0±50.0 °C(Predicted)
• 密度：
  1.250±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (3R)-3-ethyl-6-fluoro-4-(4-methoxybenzoyl)-3,4-dihydroquinoxalin-2(1H)-one 在 alkali metal carbonate 、 三氯化硼 、 四丁基碘化铵 作用下， 以 二氯甲烷 、 丙酮 为溶剂， 反应 58.08h， 生成 (3R)-3-ethyl-6-fluoro-4-(4-hydroxybenzoyl)-1-methyl-3,4-dihydroquinoxalin-2(1H)-one
  参考文献：
  名称：

  Synthesis and activity of a new class of pathway-selective estrogen receptor ligands: Hydroxybenzoyl-3,4-dihydroquinoxalin-2(1H)-ones

  摘要：

  The anti-inflammatory activity of non-selective estrogens has been attributed to their ability to antagonize the activity of nuclear factor KB (NF-kappa B), a known mediator of inflammatory responses. Here we report the identification of a potent new class of pathway-selective ER ligands that selectively antagonize NF-kappa B functional activity, while exhibiting a lack of classical estrogenic effect. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.01.001
• 作为产物：
  描述：

  2,4-二氟硝基苯 在 palladium on activated charcoal 氢气 、 potassium carbonate 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 100.0 ℃ 、344.74 kPa 条件下， 反应 31.5h， 生成 (3R)-3-ethyl-6-fluoro-4-(4-methoxybenzoyl)-3,4-dihydroquinoxalin-2(1H)-one
  参考文献：
  名称：

  Synthesis and activity of a new class of pathway-selective estrogen receptor ligands: Hydroxybenzoyl-3,4-dihydroquinoxalin-2(1H)-ones

  摘要：

  The anti-inflammatory activity of non-selective estrogens has been attributed to their ability to antagonize the activity of nuclear factor KB (NF-kappa B), a known mediator of inflammatory responses. Here we report the identification of a potent new class of pathway-selective ER ligands that selectively antagonize NF-kappa B functional activity, while exhibiting a lack of classical estrogenic effect. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.01.001

文献信息

• Estrogen receptor ligands
  申请人：Mahaney Erin Paige

  公开号：US20060019961A1

  公开（公告）日：2006-01-26

  The present invention relates to estrogen receptor ligands, and compounds and methods for treating diseases associated with excessive estrogen receptor activity.

  这项发明涉及雌激素受体配体，以及用于治疗与过度雌激素受体活性相关疾病的化合物和方法。
• US7351709B2
  申请人：——

  公开号：US7351709B2

  公开（公告）日：2008-04-01
• Synthesis and activity of a new class of pathway-selective estrogen receptor ligands: Hydroxybenzoyl-3,4-dihydroquinoxalin-2(1H)-ones
  作者：Paige E. Mahaney、Michael B. Webb、Fei Ye、Joseph P. Sabatucci、Robert J. Steffan、Christopher C. Chadwick、Douglas C. Harnish、Eugene J. Trybulski

  DOI：10.1016/j.bmc.2006.01.001

  日期：2006.5

  The anti-inflammatory activity of non-selective estrogens has been attributed to their ability to antagonize the activity of nuclear factor KB (NF-kappa B), a known mediator of inflammatory responses. Here we report the identification of a potent new class of pathway-selective ER ligands that selectively antagonize NF-kappa B functional activity, while exhibiting a lack of classical estrogenic effect. (c) 2006 Elsevier Ltd. All rights reserved.